Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof

Abstract

The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.

1 - 45 . (canceled) 
     
     
         46 . A composition formulated for administration to skin, comprising a carrier composition comprising:
 a) a short chain alcohol comprising ethanol present at a concentration of at least 55% by weight of the carrier;   b) about 2% to about 50% by weight of the carrier of a protic polar solvent comprising propylene glycol;   c) a polymeric agent comprising a cellulose ether, wherein the cellulose ether is a hydroxypropyl cellulose present at a concentration of about 0.5% to about 1% by weight of the carrier;   d) a modulating agent comprising an antioxidizing agent present at a concentration of about 0.1% to about 10% by weight of the carrier;   e) a metal;   f) an essential oil; and   g) tetracycline in a therapeutically effective amount of about 1% to about 5% by weight of the carrier;   wherein the composition is substantially nonaqueous and free or essentially free of fatty alcohol.   
     
     
         47 . The composition of  claim 46 , wherein the protic polar solvent is at a concentration of about 12% to about 30% by weight of the carrier. 
     
     
         48 . The composition of  claim 46 , further comprising a liquefied or compressed gas propellant present at a concentration of about 3% to about 25% by weight of the composition. 
     
     
         49 . A composition formulated for administration to skin, comprising a carrier composition comprising:
 a) a short chain alcohol comprising ethanol;   b) about 2% to about 50% by weight of the carrier of a protic polar solvent comprising propylene glycol;   c) a polymeric agent comprising a cellulose ether;   d) a modulating agent comprising an antioxidizing agent;   e) a metal;   f) an essential oil; and   g) tetracycline in a therapeutically effective amount of about 1% to about 5% by weight of the carrier;   wherein the composition is surfactant free, and free or essentially free of fatty alcohol.   
     
     
         50 . The composition of  claim 49 , wherein the short chain alcohol is present at a concentration of at least 55% by weight of the carrier. 
     
     
         51 . The composition of  claim 49 , wherein the cellulose ether is a hydroxypropyl cellulose. 
     
     
         52 . The composition of  claim 49 , wherein the cellulose ether is present in a concentration of about 0.5% to about 1% by weight of the carrier. 
     
     
         53 . The composition of  claim 49 , wherein the modulating agent is present at a concentration of about 0.1% to about 10% by weight of the carrier. 
     
     
         54 . The composition of  claim 49 , further comprising a liquefied or compressed propellant at a concentration of about 3% to about 25% by weight of the composition. 
     
     
         55 . The composition of  claim 49 , wherein the composition is substantially nonaqueous. 
     
     
         56 . The composition of  claim 49 , further comprising a retinoid. 
     
     
         57 . The composition of  claim 56 , wherein the retinoid comprises adapalene or tazarotene. 
     
     
         58 . A method of treating acne or rosacea, comprising administering to skin a carrier composition comprising:
 a) a short chain alcohol comprising ethanol;   b) about 2% to about 50% by weight of the carrier of a protic polar solvent comprising propylene glycol;   c) a polymeric agent comprising a cellulose ether;   d) a modulating agent comprising an antioxidizing agent;   e) a metal;   f) an essential oil; and   g) tetracycline in a therapeutically effective amount of about 1% to about 5% by weight of the carrier;   wherein the composition is surfactant free, and free or essentially free of fatty alcohol.   
     
     
         59 . The method of  claim 58 , wherein the tetracycline is a doxycycline or a minocycline. 
     
     
         60 . The composition of  claim 46 , wherein the tetracycline is a doxycycline or a minocycline. 
     
     
         61 . The composition of  claim 49 , wherein the tetracycline is a doxycycline or a minocycline. 
     
     
         62 . The composition of  claim 56 , wherein the tetracycline is a doxycycline or a minocycline. 
     
     
         63 . The method of  claim 58 , wherein the cellulose ether is a hydroxypropyl cellulose present in a concentration of about 0.5% to about 1% by weight of the carrier. 
     
     
         64 . The method of  claim 58 , wherein the modulating agent is present at a concentration of about 0.1% to about 10% by weight of the carrier.